Cortexyme (NASDAQ:CRTX) Stock Price Passes Above 200 Day Moving Average of $0.00

Cortexyme, Inc. (NASDAQ:CRTX) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $29.34. Cortexyme shares last traded at $29.34, with a volume of 197 shares.

CRTX has been the topic of several analyst reports. Canaccord Genuity initiated coverage on shares of Cortexyme in a research note on Monday, June 3rd. They issued a “buy” rating and a $42.00 target price on the stock. JMP Securities initiated coverage on shares of Cortexyme in a research note on Monday, June 3rd. They issued a “mkt outperform” rating and a $53.00 target price on the stock. Credit Suisse Group initiated coverage on shares of Cortexyme in a research note on Monday, June 3rd. They issued an “underperform” rating and a $14.00 target price on the stock. Finally, Bank of America initiated coverage on shares of Cortexyme in a research note on Monday, June 3rd. They issued a “neutral” rating and a $28.00 target price on the stock.

The business’s 50-day simple moving average is $37.39.

Institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in Cortexyme during the 2nd quarter valued at $5,926,000. Northern Trust Corp purchased a new position in Cortexyme during the 2nd quarter valued at $991,000. Bank of New York Mellon Corp purchased a new position in Cortexyme during the 2nd quarter valued at $349,000. Wells Fargo & Company MN purchased a new position in Cortexyme during the 2nd quarter valued at $191,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Cortexyme during the 2nd quarter valued at $1,052,000. 0.03% of the stock is currently owned by institutional investors and hedge funds.

About Cortexyme (NASDAQ:CRTX)

Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease.

Read More: Moving Average Convergence Divergence (MACD)

Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.